PROCEPT BioRobotics completes prostate cancer study enrollment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/2/2026

1. SPY
2. MDT
3. SPGI
4. USO
5. AAPL
6. DELL
7. NIO
8. ENOV
9. AON
10. A

Go back to PROCEPT BioRobotics completes prostate cancer study enrollment
(NASDAQ: PRCT) Delayed: 20.91 -0.29 (1.37%)
Previous Close $21.20    52 Week High $ 
Open $21.15    52 Week Low $ 
Day High $21.23    P/E N/A 
Day Low $20.33    EPS $ 
Volume 1,070,101